Docebo: ARR Reacceleration, 14% Buyback, And A Cash Flow Warning — Buy Into The Slide

Docebo Inc. (DCBO) — Upgrade to Buy

Docebo is a Buy. The stock has fallen more than two-thirds from its 52-week high of $32.85, and the Q2 earnings report delivered the kind of setup this writer looks for when buying dips: the business is turning back toward growth at a valuation that doesn't demand perfection. Revenue grew 13%, adjusted EPS beat consensus by a wide margin, organic ARR growth reaccelerated to approximately 13.9%, and management raised full-year guidance. Simultaneously, the board approved a $70 million share repurchase at $20.40 per share — covering 13.8% of the outstanding share base — an aggressive signal that management believes the stock is undervalued.

The one real red flag is Q2 cash flow, which collapsed relative to the prior year. That matters. But the thesis here is straightforward: the operating deterioration the market feared has reversed, the multiple has already priced in years of disappointment, and the next two quarters provide a clock to prove or break the call.

The ARR Story Runs Deeper Than The Headline

Docebo reported Annual Recurring Revenue — the annualized value of all active subscription contracts — of $255.1 million at June 30, up 9.5% year-over-year. Taken at face value, sub-10% ARR growth from a company that once commanded premium software multiples isn't impressive. It's also misleading.

The 9.5% figure is suppressed by three factors. The largest OEM customer, whose contribution had dominated ARR at 8.4% in mid-2025, has collapsed to just 2.5% of the total. Foreign exchange dragged $0.4 million off the top. Acquisitions add a layer of noise. Strip all three out and organic ARR growth ran approximately 13.9%. This is the second consecutive quarter of underlying reacceleration, and it's the metric that matters for whether the recurring revenue base is compounding on its own.

Even more telling is the $3.5 million upward revision to Q2 ARR guidance after the quarter closed — $1.6 million from Q2 net adds and $2.1 million flowing through to H2. Management raised enterprise assumptions based on two quarters of peak performance and strong win rates. That kind of mid-quarter upgrade doesn't happen when pipeline is weakening.

Average Contract Value grew 27% year-over-year. When ACV is climbing that fast, deal sizes are getting bigger and the revenue base is becoming stickier. That's the structural evidence that ARR growth will hold even as the favorable comparison from the OEM decline normalizes.

Revenue came in at $68.7 million, above the consensus estimate of $67.1 million. Adjusted EPS of $0.37 crushed the consensus of $0.27. Full-year guidance was raised to $274.5–276.5 million in total revenue and $54.5–56.5 million in adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization, a proxy for cash earnings before working capital swings).

The Cash Flow Warning

Q2 free cash flow was $3.1 million, or 4.5% of revenue. In the same period last year, it was $11.4 million, or 18.7% of revenue. Operating cash flow swung from generating $6.2 million to using $3.1 million. That's not a rounding error; it's a real deterioration.

The trailing-twelve-month FCF margin of 17.6% still looks solid, and TTM FCF growth is up 61% year-over-year, so Q2 is a single-quarter anomaly rather than a structural break. The timing aligns with the 365Talents integration, investment in a new Forward Deployed Engineers team, and the kind of working-capital friction that shows up during acquisition transitions. But cash flow is the filter that separates investable growth from interesting-but-fragile growth. If Q3 operating cash flow rebounds, this is a blip. If it doesn't, the story gets more complicated.

Valuation Has Reset Past The Business Deterioration

Docebo trades at a market cap of $562 million and an enterprise value of $578 million. Revenue growth is 12.7% year-over-year. The stock sits at 16.3 times trailing earnings, 2.24 times trailing sales, and a PEG ratio of 0.28. That PEG — price-to-earnings divided by the growth rate — means investors are paying 28 cents for every dollar of earnings growth. Most profitable software companies trade at PEG ratios between 1.0 and 2.0. This stock is priced as if the growth story is permanently broken rather than temporarily compressed.

Compared to Workday, the closest peer in enterprise workforce management, Docebo trades at roughly half the sales multiple — 2.24x versus Workday's 4.47x. The comparison isn't apples-to-apples, since Workday is a mature $44 billion operator, but it illustrates how far the market has discounted Docebo's growth potential. At 2.24x sales with 13% organic revenue growth and nearly 80% gross margins, the multiple is the bridge that makes this actionable.

The Buyback Is A Concrete Signal, Not Just Words

The $70 million buyback at $20.40 per share is the single most aggressive capital allocation move Docebo has made. The offer covers 13.8% of outstanding shares, which is enormous for a small-cap software company. It's funded by $10 million in cash on hand and a $60 million draw on the credit facility, which was recently expanded from $100 million to $150 million. The majority shareholder, Intercap Inc. at 63.9%, intends to participate proportionally.

The market initially punished the announcement, and for good reason. Borrowing $60 million to buy back shares while operating cash flow is negative is aggressive. It limits financial flexibility if competitive pressure intensifies or if macro conditions require a cash buffer. But it's also management putting its balance sheet behind a specific price point for the stock. A press release calling a stock undervalued is noise. A $70 million debt-funded buyback is a commitment.

The AI Narrative And What's Actually Generating Revenue

Docebo's AI story has two parts: one that's working and one that's still a roadmap.

The working part is the 365Talents acquisition. Integration is ahead of schedule. The skills-intelligence capability is driving enterprise wins — management cited the world's largest telecom company and the world's largest automotive safety supplier as Q2 wins that wouldn't have happened without it. ACV growth of 27% and the $3.5 million ARR guidance upgrade both flow from this capability being real, not theoretical.

The roadmap part is Agent Hub and Enterprise Knowledge, planned for November release, along with the Forward Deployed Engineers team that will build custom AI agent workloads for top customers. None of this is generating revenue yet. FDE costs are classified as R&D, and management reserved revenue and margin details for the November earnings call. This is the kind of unfunded narrative this analysis pressure-tests. The 365Talents evidence gives management credibility that the AI products will find paid demand, but the November release is a catalyst to watch, not a guarantee to count on.

The healthcare verticalization strategy is also worth noting. Docebo sees a $3 billion addressable market in healthcare learning within the broader $30 billion corporate learning space, and current healthcare ARR sits around $10 million. The pipeline and partner ecosystem work here could be a multi-year growth motion, but it's too early to factor into the current thesis.

Risks

Three risks determine whether this Buy holds:

• Cash flow sustainment. Q2's operating cash flow collapse is the single biggest risk. Q3 guidance calls for adjusted EBITDA of $15.9–16.1 million, which should support cash conversion if it materializes. If operating cash flow doesn't rebound, the FCF story deteriorates and the cheap multiple starts looking like a trap rather than an opportunity.
• Debt-funded buyback. Net debt rises from roughly $42 million to approximately $100 million after the $60 million facility draw for the buyback. Borrowing to retire shares during a growth inflection point is aggressive. It works only if revenue and cash flow follow through on the raised guidance.
• Favorable comparisons are temporary. Management acknowledged roughly $19 million in legacy revenue lapses over the next four quarters. That creates an easy comparison that makes growth look better than it actually is. Once that tailwind runs out, the underlying growth rate needs to stand on its own.

What Would Change This Rating

This upgrade hinges on Q3 cash flow recovery and the enterprise growth assumptions holding. If Q3 operating cash flow stays negative or turns negative again, I'd narrow this to a Hold. If Q3 guidance gets cut, this becomes a Sell. If Q3 cash flow rebounds and the November Agent Hub launch converts into visible bookings, the upside from the current level increases.

Verdict: Buy

Docebo's organic ARR growth has reaccelerated, deal sizes are getting bigger, EPS is beating expectations, and the stock trades at a PEG ratio that implies the growth story is permanently dead. It isn't. The cash flow deterioration in Q2 is real, and the debt-funded buyback adds balance-sheet risk. But the valuation reset has gone further than the business deterioration warrants, and the next two quarters provide a clear clock to test the thesis. At these levels, the risk-reward favors buyers.

Next proof point: Q3 earnings, expected late November 2026. Watch operating cash flow, Agent Hub bookings, and whether the raised enterprise assumptions materialize.